title: Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
abstract: OBJECTIVE
  The 2007 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines recommend that community-acquired pneumonia (CAP) patients admitted to hospital wards initially receive respiratory fluoroquinolone monotherapy or beta-lactam plus macrolide combination therapy. There is little evidence as to which regimen is preferred, or if differences in medical resource utilization exist between therapies. Thus, the authors compared length of hospital stay (LOS) and length of intravenous antibiotic therapy (LOIV) for patients who received initial levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily ('combination therapy').
  
  
  METHODS
  Adult hospital CAP cases from January 2005 to December 2007 were identified by principal discharge diagnosis code. Patients with a chest infiltrate and medical notes indicative of CAP were included. Direct intensive care unit admits and healthcare-associated cases were excluded. A propensity score technique was used to balance characteristics associated with initial antimicrobial therapy using multivariable regression to derive the scores. Propensity score categories, defined as propensity score quintiles, rather than propensity scores themselves, were used in the least squares regression model to assess the impact of LOS and LOIV.
  
  
  RESULTS
  A total of 495 patients from six hospitals met study criteria. Of these, 313 (63%) received levofloxacin and 182 (37%) received combination therapy. Groups were similar with respect to age, sex, most comorbidities, presenting signs and symptoms, and Pneumonia Severity Index (PSI) risk class. Patients on combination therapy were more likely to have heart failure and receive pre-admission antibiotics. Adjusted least squares mean (+/-SE) LOS and LOIV were shorter with levofloxacin versus combination therapy: LOS, 4.6 +/- 0.17 vs. 5.4 +/- 0.22 days, p < 0.01; and LOIV, 3.6 +/- 0.17 vs. 4.8 +/- 0.21 days, p < 0.01. Results for PSI risk class III or IV patients were: LOS, 5.0 +/- 0.30 vs. 5.9 +/- 0.37 days, p = 0.07; and LOIV, 3.7 +/- 0.33 vs. 5.2 +/- 0.39 days, p < 0.01. Due to the retrospective study design, limited sample size, and scope (single health-network), the authors encourage replication of this study in other data sources.
  
  
  CONCLUSIONS
  Given the LOS and LOIV reductions of 0.8 and 1.2 days, respectively, utilization of levofloxacin 750 mg daily for CAP patients admitted to the medical floor has the potential to result in substantial cost savings for US hospitals.
authors.affiliation: University of Texas at Austin, Austin, TX, USA. freic@uthscsa.edu
authors.forename: C R
authors.initials: CR
authors.lastname: Frei
authors.forename: T C
authors.initials: TC
authors.lastname: Jaso
authors.forename: E M
authors.initials: EM
authors.lastname: Mortensen
authors.forename: M I
authors.initials: MI
authors.lastname: Restrepo
authors.forename: M K
authors.initials: MK
authors.lastname: Raut
authors.forename: C U
authors.initials: CU
authors.lastname: Oramasionwu
authors.forename: A D
authors.initials: AD
authors.lastname: Ruiz
authors.forename: B R
authors.initials: BR
authors.lastname: Makos
authors.forename: J L
authors.initials: JL
authors.lastname: Ruiz
authors.forename: R T
authors.initials: RT
authors.lastname: Attridge
authors.forename: S H
authors.initials: SH
authors.lastname: Mody
authors.forename: A
authors.initials: A
authors.lastname: Fisher
authors.forename: J R
authors.initials: JR
authors.lastname: Schein
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D017963:Azithromycin / Q000627:therapeutic use*; D002443:Ceftriaxone / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000453:epidemiology; D004359:Drug Therapy, Combination; D005260:Female; D006295:Health Resources / Q000706:statistics & numerical data*; D006801:Humans; D016018:Least-Squares Analysis; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use*; D011014:Pneumonia / Q000188:drug therapy* / Q000453:epidemiology; D017410:Practice Guidelines as Topic; D012955:Societies, Medical; D014481:United States / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D002443:Ceftriaxone; D017963:Azithromycin; D015242:Ofloxacin